MediWound Ltd. Q3 2026 Earnings Call Summary Moby Intelligence Thu, November 12, 2026 at 1:18 PM EST 4 min read NVDA -4.50% MDWD -4.56% Explore stocks on Coinbase Trading disclosure Trading disclosure The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.
NexoBrid achieved its strongest quarterly revenue to date in the U.S., driven by record hospital orders and a higher number of new ordering centers in the first nine months of 2026 than in all of 2025.
Global demand for NexoBrid currently exceeds existing manufacturing capacity, necessitating a strategic prioritization of the U.S. market and BARDA procurement over European and Japanese markets.
Gross margin improved to 28.5% primarily due to a higher contribution from royalty revenue, which carries a higher margin profile than development services.
The company views EscharEx as a uniquely attractive strategic asset for large wound care companies because it is the only late-stage BLA candidate currently addressing a market shift toward products with established reimbursement paths.
R&D expenses increased to $6.2 million, reflecting the prioritized investment in the EscharEx Phase III VALUE trial as it moves toward critical enrollment milestones.
Management successfully secured the current facility's GMP certification for an additional two years following routine inspections by the FDA and Israeli Ministry of Health.
The 2026 revenue outlook is heavily dependent on the timing of securing U.S. government funding for a planned domestic manufacturing facility, which remains an ongoing and uncertain discussion.
Top-line results for the EscharEx VALUE trial are anticipated in mid-2027, assuming the interim sample size reassessment in Q1 2027 confirms the current 216-patient design.
Commercial supply from the expanded NexoBrid manufacturing facility is expected in the second half of 2027, following the completion of modifications in Q4 2026 and subsequent regulatory approval.
Management expects R&D spending to decline substantially following the completion of the Phase III VALUE trial, shifting the financial focus toward commercialization and additional indications.
The company plans to initiate clinical trials for diabetic foot ulcers and pressure ulcers shortly, with the pressure ulcer study being investigator-initiated and the DFU study supported by the European Innovation Council.
The Department of War awarded an additional $3.3 million in nondilutive funding for a room-temperature-stable NexoBrid formulation, bringing the total program budget to $21.8 million.
A November 2026 public offering generated $17.25 million in gross proceeds, providing financial flexibility through the anticipated VALUE trial data readout.
A substantial portion of anticipated 2026 revenue is tied to development services for the U.S. manufacturing project, creating significant variability in near-term financial results.
The Independent Data and Safety Monitoring Board recommended the VALUE trial continue without modifications following a periodic safety review.
One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.
Management expressed high confidence in the timeline for completing enrollment by the end of the first quarter of 2027. now that nearly all sites are open, having resolved previous logistical 'hiccups' related to opening European sites.
The company is maintaining study integrity by not sharing specific enrollment trends but confirmed the 40 active sites support the Q1 2027 target.
Management noted that 8 of the 9 largest wound care companies are already collaborating with MediWound, highlighting the asset's potential to disrupt the $400 million annual sales of legacy products like SANTYL.
The shift in CMS reimbursement for skin substitutes has increased the strategic value of EscharEx as a BLA-track candidate with a clear reimbursement path.
The DSMB will specifically evaluate the 'time to wound closure' endpoint after 140 patients finish treatment to confirm 85% statistical power.
Management clarified that the 'incidence of complete debridement' endpoint is already highly powered and unlikely to require a sample size increase.
The company is selling every unit it can manufacture and is currently forced to prioritize U.S. commercial needs and BARDA procurement over other global demand.
The expanded facility is expected to alleviate these constraints in the second half of 2027, but no earlier due to the required regulatory review and inspection process.
